Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT719 in relapsed/refractory CD19-positive B-cell malignancies
NCT07131254Phase 1Recruiting
- Sponsor
- Grit Biotechnology
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GT719 in B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia (ALL), sponsored by Grit Biotechnology. Primary endpoints: Adverse Events at 28 days and Dose Limiting Toxicity at 28 days. Started Mar 2025; status: recruiting.
02
Drugs
GT719
03
Conditions
B-cell non-Hodgkin lymphomaacute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07131254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07131254.